Objective: The aim of this study was to clarify myocardial involvement and its clinical implications in subjects with spinal and bulbar muscular atrophy (SBMA), a neuromuscular disease affecting both neuronal and nonneuronal tissues.
Spinal and bulbar muscular atrophy (SBMA), or Kennedy disease, is a hereditary neuromuscular disease caused by the expansion of a trinucleotide CAG repeat in the androgen receptor (AR) gene.
1,2 SBMA occurs predominately in adult males. 3, 4 The accumulation of the pathogenic AR proteins in the nucleus of motor neurons is central to the pathogenesis of this disease. 5 In addition to neuromuscular deficits, nonneuronal symptoms such as gynecomastia, muscle cramps, hypertension, hyperlipidemia, and liver dysfunction are often observed in patients with SBMA. 4, 6 While gynecomastia and other symptoms of androgen insensitivity appear to result from the partial loss of AR function, the remaining nonneuronal symptoms are likely due to toxicity of the pathogenic AR in these tissues. 7, 8 In particular, the elevated serum levels of creatine kinase together with histopathologic findings of myopathic changes indicate the role of skeletal muscle damage in the pathogenesis of SBMA.
found that subjects with SBMA may show Brugada-type ECG, which is an ECG representation of a coved or saddle-back-type STsegment elevation in $1 lead among the right precordial leads V [1] [2] [3] , and is associated with sudden death. 13, 14 METHODS Patients. Subjects were 144 consecutive Japanese subjects with SBMA (aged 52.1 6 10.1 years). We included genetically confirmed male Japanese subjects with more than one of the following symptoms: muscle weakness, muscle atrophy, or bulbar palsy. The subjects were excluded if they met any of the following criteria: (1) severe complications such as malignancy; (2) other neurologic complications; (3) had taken hormonal agents within 48 weeks before informed consent; or (4) participated in any other clinical trials before informed consent. All subjects were outpatients and were followed in Nagoya University Hospital. The data were collected between February 2002 and August 2012.
Evaluation of ECG. Standard 12-lead ECG was recorded from
all of the participants and evaluated by 2 independent cardiologists. The diagnosis of the Brugada-type ECG or Brugada syndrome was made on the basis of the second consensus conference. 14 In the subjects with Brugada-type abnormality on standard 12-lead ECG, we also examined ECG in which the right precordial leads were placed to the third intercostal spaces for classifying 3 types of Brugada-type ECGs. We did not perform the sodium channel blocker challenge test in subjects with type 2 or 3 Brugada-type ECG.
Evaluation of disease severity and serologic parameters.
We evaluated disease severity using the revised Amyotrophic Lateral Sclerosis Functional Rating Scale, a validated questionnairebased scale that measures physical function performing activity of daily living as described previously. 15 We defined the onset of disease as the time when muscle weakness began, but not when tremor of the fingers appeared. Serum levels of testosterone were measured by radioimmunoassay in the subjects who were evaluated until 2006 and by chemiluminescent immune assay in the others.
Histopathology. We analyzed autopsied myocardial specimens of 7 genetically diagnosed subjects with SBMA and 4 sex-and age-matched control subjects (aged 66.7 6 9.7 and 69.5 6 5.8 years at the time of death, respectively) using immunohistochemistry. Pathologic diagnoses of the controls were malignant lymphoma, dementia with Lewy bodies, corticobasal degeneration, and progressive supranuclear palsy. The myocardia were excised at autopsy and fixed immediately in 10% buffered formalin solution. Sections (6 mm) were deparaffinized, treated with microwave heating for 10 minutes in 10 mM citrate buffer at pH 6.0, and incubated with primary antibodies. Subsequent staining procedures were performed using the Envision1 kit (Dako, Glostrup, Denmark) as described previously. 16 For anti-polyglutamine staining, sections were treated with 98% formic acid at room temperature for 3 minutes before the antigen retrieval with the microwave. We used the following primary antibodies: AR (N-20, 1:1,000; Santa Cruz Biotechnology, Dallas, TX); SCN5A (sc-22758, 1:1,000; Santa Cruz); and polyglutamine 1C2 (MAB1574, 1:20,000; Millipore Corp., Billerica, MA).
Immunoblotting. We analyzed autopsied myocardial specimens of 4 genetically diagnosed subjects with SBMA and 4 sex-and age-matched control subjects (aged 66.8 6 11.0 and 69.5 6 5.8 years at the time of death, respectively) using immunoblotting. Autopsied myocardial specimens were homogenized in CelLytic lysis buffer (Sigma-Aldrich, St. Louis, MO) containing a phosphatase inhibitor cocktail (Sigma-Aldrich) and a protease inhibitor cocktail (Thermo Scientific, Waltham, MA). Homogenates were then centrifuged at 2,500g for 10 minutes at 4°C. The supernatant fractions were separated on 5% to 20% SDS-polyacrylamide gel electrophoresis gels and transferred to Hybond-P membranes (GE Healthcare, Buckinghamshire, UK). Primary antibody binding was probed using horseradish peroxidaseconjugated secondary antibodies (GE Healthcare) at a dilution of 1:5,000, and bands were detected using the ECL prime kit (GE Healthcare). The immunoblots were digitalized (LAS-3000 imaging system; Fujifilm), signal intensities were quantified with Image Gauge software version 4.22 (Fujifilm), and the means 6 SEM were expressed in arbitrary units. The following primary antibodies were used: anti-SCN5A (sc-23174, 1:1,000; Santa Cruz) and anti-GAPDH (MAB374, 1:5,000; Millipore).
Quantitative real-time PCR. Quantification of messenger RNA levels was determined by real-time PCR as described previously. 17 Briefly, total RNA was extracted from autopsied myocardium using RNeasy Fibrous Tissue Midi Kit (Qiagen, Venlo, Limburg). The extracted RNA was reverse-transcribed into first-strand complementary DNA using SuperScript III reverse transcriptase (Invitrogen). Detailed methods for realtime PCR are described in appendix e-1 on the Neurology ® Web site at Neurology.org.
Genetic analysis. Genomic DNA was extracted from peripheral blood of subjects with SBMA using conventional techniques. PCR amplification of the CAG repeat in the AR gene was performed using a fluorescein-labeled forward primer (59-TCCAGAATCTGTTCCAGAGCGTGC-39) and a nonlabeled reverse primer (59-TGGCCTCGCTCAGGATGTCTTTAAG-39). Detailed PCR conditions were described previously. 18 Aliquots of PCR products were combined with loading dye and separated by electrophoresis with an autoread sequencer (SQ-5500; Hitachi Electronics Engineering, Tokyo, Japan). In subjects with Brugada-type ECGs, we screened for sodium channel, voltagegated, type V, a subunit (SCN5A), calcium channel, voltagedependent, L type, a 1C subunit (CACNA1C), and calcium channel, voltage-dependent, b 2 subunit (CACNB2) mutations, which are representative genes linked to Brugada syndrome, using a high-resolution melting method or denaturing highperformance liquid chromatography (WAVE system model 3500; Transgenomic, Omaha, NE) and subsequent direct sequencing, as previously reported. 19, 20 Standard protocol approvals, registrations, and patient consents. This study adhered to the Ethics Guidelines for Human Genome/Gene Analysis Research and those for Epidemiological Studies endorsed by the Japanese government, and was approved by the Ethics Committees of Nagoya University Graduate School of Medicine, Kyoto University Graduate School of Medicine, and Shiga University of Medical Science. All participants provided written informed consent. The collection of autopsied human tissues and their use for this study were also approved by the Ethics Committee of Nagoya University Graduate School of Medicine, and written informed consent was obtained from the subjects' next of kin. Experimental procedures involving human subjects were conducted in conformance with the principles expressed in the Declaration of Helsinki.
Statistical analysis. All data are presented as means 6 SD.
Intergroup differences in categorical and continuous variables were assessed using the x 2 test and unpaired t test, respectively. A p value ,0.05 was considered to indicate significance. Calculations were performed using the statistical software package SPSS 20.0J (SPSS Japan, Tokyo, Japan).
RESULTS

Patient demographics and blood profiles.
The clinical and hematologic features of the 144 subjects with SBMA are described in table 1. The characteristics of the present study population, such as age at examination, age at onset, and CAG repeat length, were similar to those of previous studies. 21, 22 Hypertension, hypercholesterolemia, and hypertriglyceridemia were observed in 37.6%, 41.7%, and 49.3% of the subjects, respectively. Histories of cardiovascular disease included angina in 4 cases, and myocardial infarction, aortic regurgitation, bradycardia, pulmonary artery stenosis with ventricular septal defect, arrhythmia, cardiac hypertrophy, or aortic dissection in one case each.
ECG abnormalities. Seventy (48.6%) of 144 subjects showed an abnormal ECG. The most frequent findings were ST-segment abnormalities in V 1-3 (19.4%), followed by ST-segment abnormalities in I, aVL, V 5-6 (18.1%), left ventricular hypertrophies (9.7%), ST-segment abnormalities in II, aVF (7.6%), and right bundle branch blocks (5.6%). Among the ST-segment abnormalities in right precordial leads (V 1-3 ), the most common feature was Brugada-type ECGs, which were detected in 17 of 144 subjects (11.8%) in our cohort. The Brugada-type ECGs in subjects with SBMA were classified into 3 subtypes 13 : type 1 in 6 subjects, type 2 in 7 subjects, and type 3 in 4 subjects.
Case reports. Two subjects were diagnosed with symptomatic Brugada syndrome among the 17 cases with Brugada-type ECG. One of these subjects experienced syncope, and both of them had sudden death. The detailed clinical findings of these subjects are described below. Case 1. Case 1 (patient 1 in table e-1), a 75-year-old man with a history of SBMA, presented with syncope. His medical history included benign prostatic hyperplasia and glaucoma, but he did not have any heart diseases. At the age of 40 years, he experienced the first syncope and medical examination revealed a right bundle branch block. He noticed muscle weakness of his limbs at age 65 years and was diagnosed with SBMA by genetic screening (CAG repeat length was 46). He had his second syncope after drinking at the age of 78 years but regained consciousness 5 minutes later. His ECG showed type 2 Brugada ECG (figure 1A). Neither his echocardiogram nor iodine-123-b-methyl iodophenyl pentadecanoic acid myocardial scintigram demonstrated any detectable left ventricular dysfunction (figure 1, B and C). There were no abnormalities in heart coronary arteries with contrast, but the electrophysiologic study induced ventricular tachycardia by extra-stimuli from the right ventricular outflow tract, in which the basic ventricular stimulation period was 500 milliseconds, and 2 consecutive stimulation periods were 220 and 180 milliseconds ( figure 1D ). He received an implantable cardioverter defibrillator under the diagnosis of Brugada syndrome, but it was removed 2 years later because of a bacterial infection. At age 82 years, he was hospitalized for pneumonia and dehydration, and died suddenly when he was sleeping at night. His last temperature was 37.5°C. His sodium and potassium levels on the date of death were 164 and 3.6 mEq/L (normal ranges were 138-146 and 3.6-4.9 mEq/L), respectively. No autopsy was performed on this subject. Case 2. Case 2 (patient 2 in table e-1), a 68-year-old man with a history of SBMA, presented with sudden death. His medical history was unremarkable except for high blood pressure, diabetes mellitus, traumatic subarachnoid hemorrhage, and spasmodic deafness. He noticed dysphagia and muscle weakness of his limbs at the age of 50 years. He was diagnosed with SBMA by genetic screening (CAG repeat length was 50). At age 70 years, he suddenly lost consciousness at the moment when he moved to a dining table with the assistance of his family at night, following loss of appetite for 1 week. His sodium and potassium levels were 115 and 3.8 mEq/L, respectively. His ECG showed pulseless electrical activity with ST elevations in V 1-4 (type 1 Brugada ECG) ( figure 1E ). Despite cardiopulmonary resuscitations, he died 23 minutes after the onset of unconsciousness. A mild bronchial pneumonia, a mild ischemia-related heart change, and arteriosclerosis of coronary arteries were indicated at autopsy, but histopathologic analysis did not identify the direct cause of death. Acute heart failure due to arrhythmia was suspected as the cause of death.
Clinical features of the subjects with Brugada-type ECGs.
Longer CAG repeat sizes and higher serum testosterone levels tended to occur in subjects with Brugada-type ECGs compared with those without Brugada-type ECGs, but there was no statistically significant difference between the groups in clinical features and blood chemical values (table 2) . PQ and QRS intervals were also equivalent between the groups. The details of 17 subjects with SBMA and Brugada-type ECG are shown in table e-1. One of 14 subjects who underwent echocardiography had a right ventricular overload and mild tricuspid regurgitation, whereas no evidence of myocardial dysfunction was found in the remaining 13 subjects. None of the 17 subjects with Brugada-type ECGs had family histories of sudden cardiac deaths at an age younger than 45 years, symptomatic bradycardia, or coved-type ECGs in their family members. Genetic analysis demonstrated no known gene mutations in conjunction with Brugada syndrome in the 17 subjects, including SCN5A, CACNA1C, and CACNB2 genes.
Histopathologic and biochemical study. Histopathologic analyses of the myocardium revealed nuclear accumulation of the pathogenic AR in all 7 autopsied subjects with SBMA ( figure 2A ), of which one had symptomatic Brugada syndrome as described above (case 2). Hematoxylin & eosin staining showed no detectable abnormalities, except for one subject with increased fat tissue within the right ventricle myocardium, which was reported previously in subjects with Brugada syndrome (figure 2B). 23 To elucidate the molecular basis of Brugada-type ECG in SBMA, we investigated the gene expression of ion channels that are firmly linked to Brugada syndrome. The results of quantitative real-time PCR showed a marked decrease in messenger RNA levels of SCN5A but not CACNA1C or CACNB2 in the myocardium of subjects with SBMA (figure 2, C-E). Decreased protein levels of SCN5A were also detected by immunoblot (figure 2, F and G) and immunohistochemistry ( figure 2H ).
DISCUSSION In the present study, we demonstrated that subjects with SBMA exhibit several forms of ECG abnormalities. The most striking observation in our cohort is that Brugada-type ECG was observed in more than 10% of the subjects with SBMA. Of those, 2 subjects reported symptomatic Brugada syndrome, leading to sudden death. Although sudden death by neuronal loss in the intermediolateral nucleus was reported in amyotrophic lateral sclerosis, 24 there are no reports of Brugada syndrome, suggesting that this type of ECG appears to be specific to SBMA.
Brugada syndrome may cause sudden death by ventricular fibrillation at an average age of 41 years, without structural heart problems. 14, 25 This syndrome may be responsible for 4% to 12% of all sudden deaths, and at least 20% of sudden deaths in patients with structurally normal hearts. Brugada-type ECG is observed frequently in asymptomatic patients. 26 Given that the frequency of Brugada-type ECG is reported to be 0.15% to 1.22% in Japanese community-based populations, 27, 28 our study suggests a very high prevalence of Brugada-type ECGs in SBMA and implies a link between the pathogenesis of the disorders, although we cannot fully exclude the possibility of a chance association of these 2 conditions. In this regard, it is intriguing that SBMA and Brugada syndrome share common clinical features. Both diseases are characterized by male predominance. SBMA affects males exclusively, whereas females with homozygous mutation of the AR gene manifest no neuromuscular phenotype. 29 Similarly, Brugada syndrome is known to show a high male predominance (80%-90%).
14 The pathologic process of SBMA is dependent on circulating levels of testosterone, 5, [30] [31] [32] and high testosterone levels increase the risk of Brugada syndrome via intensifying ionic current imbalance in the myocardium. 33 These commonalities may underlie the high prevalence of Brugada-type ECGs in SBMA. Although another epidemiologic study in 25 European patients with SBMA showed no ECG abnormalities, 34 the discrepancy between this and our studies may be attributable to the difference in the sample size and ethnic background. Brugada syndrome is more common in Asian than Caucasian populations, 14, 25, 35 which may contribute to the high occurrence of Brugada-type ECGs in Japanese subjects with SBMA in the present study.
Typical Brugada-type ST elevation (J point elevation) results from an ion current imbalance across cardiac cell membrane, which is induced by the malfunction of cardiac ion channels governing the action potential. Mutations in genes encoding these ion channels or their modulating proteins have been shown to be causative of Brugada syndrome. Among them, mutations in SCN5A, which encodes the a subunit of cardiac sodium channel, have been reported in 10% to 30% of patients with Brugada syndrome.
14 Although much less frequent, several other causative genes have also been identified, including the L-type calcium channel (CACNA1C and CACNB2), glycerol-3-phosphate dehydrogenase 1-like channel, and potassium channels. Recently, a genome-wide association analysis also identified susceptibility loci at SCN5A, SCN10A, and the HEY2 genes for Brugada syndrome. 36 Although none of our subjects with Brugada-type ECG had mutations in SCN5A, CACNA1C, or CACNB2, histopathologic and biochemical analyses indicated downregulation of SCN5A gene expression in the myocardium of subjects with SBMA. Given that the mutations in the SCN5A gene are shown to culminate in functional loss of the sodium channels, 37 decreased expression of this gene in the myocardium may be associated with the pathogenesis of myocardial involvement in SBMA. Nonneuronal cells, such as hepatocytes and epithelial cells of scrotal skin, show the accumulation of the pathogenic AR, which, at least partially, corresponds to clinical symptoms and findings of SBMA. 8 Nuclear accumulation of the pathogenic AR induces transcriptional dysregulation, leading to altered expression of several genes in skeletal muscles, as well as the spinal cord. 38, 39 Taken together, gene expression abnormalities due to the nuclear accumulation of pathogenic AR may result in myocardial dysfunction in SBMA.
In the present study, we detected no differences in clinical and genetic features between SBMA subjects with and without Brugada-type ECG, but severe hyponatremia in the subject with symptomatic Brugada syndrome (case 2) suggests that patients with SBMA have the potential risk of Brugada syndrome at basal conditions and that certain triggers (such as hyponatremia) may enhance the electrophysiologic deficits in the myocardium and manifest Brugadatype ECGs or fatal ventricular arrhythmias. This hypothesis is consistent with the observation that Brugada ECG patterns may be modulated by numerous factors, including the autonomic nervous system, altered levels of electrolytes, heavy meals, and high body temperature. 26 In particular, hypokalemia in conjunction with hyponatremia is reported to precipitate Brugada syndrome, as shown in the present study. 40 Although respiratory tract infections due to bulbar palsy are common at advanced stages of SBMA, the cause of death is not determined in a certain population. 21 Our results indicate that sudden death due to fatal arrhythmias associated with Brugada syndrome may occur in patients with SBMA. Because subjects with Brugada type 1 ECG are often symptomatic and at a high risk of sudden death, it is important to examine ECGs in patients with SBMA and to carefully manage subjects with Brugada-type ECG abnormalities.
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